Showing 101-110 of 9741 results for "".
Eyeing a Treatment for Syringoma
https://practicaldermatology.com/series/scientifically-speaking/eyeing-a-treatment-for-syringoma/20112/Listen as Joel L. Cohen, MD describes early evidence for the use of nano pulse stimulation to treat syringoma, a notoriously challenging target.Scientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneDermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraEnsuring Excellent Care Across LGBTQ and Sexual Minority Patients
https://practicaldermatology.com/topics/practice-management/ensuring-excellent-care-across-lgbtq-and-sexual-minority-patients/20077/The session on LGBTQ and sexual gender minority health covered a range of topics including both clinical care as well as terminology, structures, and framework. Klint Peebles, MD talks about the importance of providing excellent dermatologic care as patients face disparities and challenges in accessThe Art of Patient Scheduling
https://practicaldermatology.com/topics/practice-management/the-art-of-patient-scheduling/23676/Is your patient scheduling system working as efficiently as possible? Put these five action items in place to ensure your practice is firing on all cylinders.Scientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new canc